On Nov 08, major Wall Street analysts update their ratings for $Arcellx (ACLX.US)$, with price targets ranging from $111 to $115.
Morgan Stanley analyst Judah Frommer maintains with a buy rating, and adjusts the target price from $106 to $111.
TD Cowen analyst Tyler Van Buren maintains with a buy rating.
William Blair analyst Sami Corwin maintains with a buy rating.
H.C. Wainwright analyst Emily Bodnar maintains with a buy rating, and adjusts the target price from $95 to $115.
Furthermore, according to the comprehensive report, the opinions of $Arcellx (ACLX.US)$'s main analysts recently are as follows:
The probability of success for anito-cel has been revised upwards after reviewing the preliminary results from the Phase 2 iMMagine-1 trial in patients with relapsed/refractory multiple myeloma. There is a significant opportunity for market share capture, first targeting treatment in later stages and potentially in earlier stages if the current clinical outcomes are maintained.
The firm's analysis suggests that recent abstracts, which encompass initial Phase 2 results and extended Phase 1 data, support the competitive position and regulatory progress of pivotal-stage anito-cel in treating multiple myeloma. Despite a decline in share value, this is perceived as a 'sell the news' event following a substantial pre-abstract increase. It is now anticipated that anito-cel will secure a more formidable peak market share and exhibit greater likelihood of success.
The firm expressed increasing optimism following the updated clinical data release. The publication of ASH abstracts, notably the initial data from the registrational IMMagine-1 study, contributed to this positive outlook.
Here are the latest investment ratings and price targets for $Arcellx (ACLX.US)$ from 4 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美东时间11月8日，多家华尔街大行更新了$Arcellx (ACLX.US)$的评级，目标价介于111美元至115美元。
摩根士丹利分析师Judah Frommer维持买入评级，并将目标价从106美元上调至111美元。
TD Cowen分析师Tyler Van Buren维持买入评级。
威廉博莱分析师Sami Corwin维持买入评级。
H.C. Wainwright分析师Emily Bodnar维持买入评级，并将目标价从95美元上调至115美元。
此外，综合报道，$Arcellx (ACLX.US)$近期主要分析师观点如下：
通过审阅第2期iMMagine-1试验初步结果，anito-cel成功的概率已上调，在复发/难治性多发性骨髓瘤患者中。在市场上占有份额的重大机会，首次针对后期治疗，并且在当前临床结果得以维持的情况下，有可能扩大至较早期阶段。
该公司的分析表明，最近的摘要涵盖了初步第2期结果和延长的第1期数据，支持关键阶段的anito-cel在治疗多发性骨髓瘤中的竞争地位和监管进展。 尽管份额价值下降，但这被视为跟随大幅上涨的成果的``卖出速报'' 事件。 预计anito-cel将获得更具威胁性的最高市场份额，并表现更具成功可能性。
该公司在更新的临床数据发布后表达出了日益乐观的态度。ASH摘要的发布，特别是来自登记iMMagine-1研究的初步数据，为这一积极展望做出了贡献。
以下为今日4位分析师对$Arcellx (ACLX.US)$的最新投资评级及目标价：
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
